SCHEMBL29638838

SCHEMBL29638838

CCN(CC)C(=O)C1[C@H]2CN(C(=O)OC(C)(C)C)C[C@@H]12

nearest known ligand 0.47

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
NR1H2 P55055 1/20 0.47
JAK3 P52333 1/20 0.39
MEN1 O00255 1/20 0.39
ALDH1A1 P00352 1/20 0.39
MAPT P10636 1/20 0.39
KMT2A Q03164 1/20 0.39
USP2 O75604 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
SSTR4 P31391 1/20 0.38
DDB1 Q16531 1/20 0.37
CRBN Q96SW2 1/20 0.37
NAMPT P43490 1/20 0.37
HPGD P15428 1/20 0.36
GPR119 Q8TDV5 5/20 0.35
RECQL P46063 1/20 0.35
EPHX1 P07099 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21349508 1.00 NR1H2 (0.47) NR1H2JAK3MEN1ALDH1A1MAPT
SCHEMBL21349507 0.87 NR1H2 (0.46) NR1H2JAK3MEN1ALDH1A1MAPT
SCHEMBL22990028 0.84 NR1H2 (0.49) NR1H2JAK3MEN1ALDH1A1MAPT
SCHEMBL21137360 0.84 HPGD (0.41) MEN1ALDH1A1MAPTKMT2AUSP2
SCHEMBL14606052 0.83 NR1H2 (0.46) NR1H2JAK3MEN1ALDH1A1MAPT
SCHEMBL5591325 0.83 NR1H2 (0.46) NR1H2JAK3MEN1ALDH1A1MAPT
SCHEMBL20585864 0.81 NR1H2 (0.34) NR1H2MEN1ALDH1A1MAPTKMT2A
SCHEMBL20585866 0.81 NR1H2 (0.34) NR1H2MEN1ALDH1A1MAPTKMT2A
SCHEMBL30241681 0.80 KDM5A (0.46) NR1H2JAK3MEN1ALDH1A1MAPT
SCHEMBL21350249 0.80 NR1H2 (0.50) NR1H2JAK3MEN1ALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3638658-B1 PHARMACEUTICAL COMPOUNDS NXERA PHARMA UK LTD (GB) 2025-10-08 EP disclosed
CN-110944992-B Pharmaceutical compounds 赫普泰雅治疗有限公司 2023-05-16 CN disclosed
US-11352342-B2 Pharmaceutical compounds HEPTARES THERAPEUTICS LIMITED (GB) 2022-06-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11352342-B2 Pharmaceutical compounds CHRM1, CHRM2, CHRM4 NR1H2 234/4885JAK3 3206/4885MEN1 219/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.